Jan 16, 2019 · Glimepiride does not accumulate in serum following multiple dosing
Glimepiride works by stimulating the secretion of insulin granules from pancreatic
Pharmacokinetics Gastrointestinal absorption is complete, with no interference
To determine the pharmacokinetics of glimepiride, a sulfonylurea antidiabetic agent
Evogliptin, a dipeptidyl peptidase-4 inhibitor, and glimepiride, a
Mechanism of Action: Glimepiride, an antidiabetic sulfonylurea, reduces blood glucose by stimulating the insulin release from pancreatic β-cells and decreases glucose output from the liver
The pharmacokinetics of glimepiride does not differ between healthy subjects and patients with type 2 diabetes
1 DM is one of the main causes of death in adults, which caused four million deaths globally in 2017
When colesevelam is coadministered with glimepiride, maximum plasma concentration and total exposure to glimepiride is reduced
Clearance of glimepiride after oral administration does not change over the 1 mg to 8 mg dose range, indicating linear pharmacokinetics
Comparison of glimepiride pharmacokinetics in Type 2 diabetic patients ≤65 years and those >65 years was performed in a study using a dosing regimen of 6 mg daily
Clinical Pharmacology & Therapeutics (2002) 72, 326–332; doi: 10
The pharmacokinetics of glimepiride does not differ between healthy subjects and patients with type 2 diabetes
However, the PK profiles of a combination drug containing glimepiride and sustained-release (SR) metformin have not been reported
There were no significant differences in glimepiride pharmacokinetics between the two age groups
A comparison of glimepiride pharmacokinetics in patients with type 2 diabetes ≤65 years and those >65 years was evaluated in a multiple-dose study using glimepiride 6 mg daily
There were no significant differences in glimepiride pharmacokinetics between the two age groups
A comparison of glimepiride pharmacokinetics in patients with type 2 diabetes ≤65 years and those >65 years was evaluated in a multiple-dose study using glimepiride tablets 6 mg daily
The mean AUC at steady state for the older patients was approximately The recommended starting dose of glimepiride tablets are 1 mg or 2 mg once daily
5, 8
Both drugs are certified to be mainly metabolized via cytochrome P450 (CYP) 2C9 in vivo and may have the potential drug-drug interactions
73 m^2